Polyrizon initiates preclinical studies for intranasal naloxone targeting opioid overdose based on its innovative t&t platform

Raanana, israel, march 10, 2025 (globe newswire) -- polyrizon ltd. (nasdaq: plrz) (the "company" or "polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal naloxone, a life-saving opioid overdose treatment.
PLRZ Ratings Summary
PLRZ Quant Ranking